Publications by authors named "M L Sponziello"
Article Synopsis
- Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and this study examined the potential of two microRNAs, miR-146a-5p and miR-221-3p, as biomarkers for diagnosing and monitoring PTC.
- The researchers conducted an observational study with PTC patients and healthy controls, analyzing levels of these microRNAs through digital PCR before and after surgery.
- Results showed that both microRNAs are effective in differentiating PTC patients from healthy individuals, with specific fold changes indicating disease progression, making them useful for ongoing patient monitoring.
Purpose: Multitarget kinase inhibitors (MKIs) are effective options in the treatment of cancer, significantly increasing the progression-free survival (PFS) of many tumors. Data about severity and prevalence of metabolic adverse events is scarce and may be significant in patients with a better survival. The aim of this study was to investigate glucose and lipids values of patients treated with lenvatinib.
View Article and Find Full Text PDFArticle Synopsis
- * Recent advancements in diagnostic methods, like TIRADS, help predict the risk of malignancy, potentially reducing the need for biopsies, though larger nodules still require cytological evaluation.
- * Management strategies now include options like active surveillance and local treatments instead of solely relying on surgery, supported by shared decision-making tools for better clinician-patient communication.
Resistance to thyroid hormone (RTH) is a rare autosomal dominant disease characterized by an alteration of thyroid hormone negative feedback, usually as a consequence of a mutation in the thyroid hormone receptor-b gene (THRβ). It is characterized by high variability of clinical manifestations, ranging from isolated abnormal thyroid function tests without symptoms to severe and impaired clinical conditions. Here we report the case of a woman who was diagnosed with RTHβ when she was 35 years old and was treated with 3,5,3-triiodiothyroacetic acid (TRIAC) because of the onset of clinical symptoms of hyperthyroidism.
View Article and Find Full Text PDF